# Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

> **NCT00455910** · PHASE2 · COMPLETED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 112 (—)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00455910
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 112 (—)
- **Last updated:** 2007-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00455910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00455910, "Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00455910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*